Ovensa deal with Takeda to deliver an antibody to the brain

Canadian preclinical stage company Ovensa today announce that it has entered into a collaboration agreement with Japan’s Takeda Pharmaceutical (TYO: 4502) to evaluate Ovensa's proprietary nanomedicine platform called Triozan for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

"We are extremely proud of this new partnership, which demonstrates a great deal of confidence in our unique delivery system which helps therapeutic molecules better cross the human body's various barriers such as the skin, the mucous membranes or the blood-brain barrier and reach their target. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. We are starting this collaboration with enthusiasm and hope that this partnership will accelerate the discussions we have with some 30 other companies, "says Ovensa's president and chief executive Stéphane Gagné.

Although Ovensa's platform research focuses on complex diseases for which there are few available treatments such as brain cancer and Alzheimer's disease, it also applies to other therapeutic areas such as metabolic diseases, animal health or antibiotic resistance. Also using its patented Triozan, Ovensa is conducting trials with its collaborators to develop new custom nanomedicines using cannabinoids such as cannabidiol (CBD) to treat various diseases including certain cancers, diseases of the central nervous system and pain.